Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.30 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.30 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8131036 | 0.87 | DAGLA (0.32) | CYP11B1CYP11B2 | |
| SCHEMBL8575164 | 0.85 | — | — | |
| SCHEMBL1121836 | 0.84 | NOTUM (0.35) | CYP11B1CYP11B2L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL18982574 | 0.83 | NOTUM (0.34) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL752388 | 0.83 | POLB (0.33) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL5603377 | 0.81 | TRPV1 (0.42) | RAB9AL3MBTL1TSHR | |
| SCHEMBL12327489 | 0.80 | DAGLA (0.35) | CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL30343520 | 0.80 | POLB (0.32) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL6046474 | 0.79 | KDM4E (0.35) | CYP11B1CYP11B2POLBSMN1; SMN2KCNN4 | |
| SCHEMBL22832703 | 0.79 | IDO1 (0.36) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2024-08-27 | — | — | US | disclosed |
| EP-3380970-B1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INST (US) | 2023-01-04 | — | — | EP | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | NAVITOR PHARMACEUTICALS, INC. (US) | 2022-05-24 | — | — | US | disclosed |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2022-05-12 | — | — | US | disclosed |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | NAVITOR PHARMACEUTICALS, INC. | 2021-08-05 | — | — | US | disclosed |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2020-11-05 | — | — | US | disclosed |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | Sanford Burnham Prebys Medical Discovery Institute (US) | 2020-04-21 | — | — | US | disclosed |
| US-5939443-A | ANTIDIABETIC AGENTS AND TREATMENT OF OBESITY | ELI LILLY AND COMPANY (US) | 1999-08-17 | — | — | US | disclosed |
| WO-1999029673-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1999-06-17 | — | — | WO | disclosed |
| EP-0921120-A1 | Selective beta 3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1999-06-09 | — | — | EP | disclosed |
| US-5840738-A | Selective β-3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-11-24 | — | — | US | disclosed |
| US-5808080-A | Selective β3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-09-15 | — | — | US | disclosed |
| US-5786356-A | TREATING TYPE II DIABETES, OBESITY | ELI LILLY AND COMPANY (US) | 1998-07-28 | — | — | US | disclosed |
| WO-1998009625-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| EP-0827746-A1 | Carbazole analogues as selective B3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1998-03-11 | — | — | EP | disclosed |
| WO-1997010825-A1 | SELECTIVE β3 ADRENERGIC AGONISTS | ELI LILLY AND COMPANY (US) | 1997-03-27 | — | — | WO | disclosed |
| EP-0764640-A1 | Selective beta3 adrenergic agonists | ELI LILLY AND COMPANY (US) | 1997-03-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210238165-A1 | HETEROARYL RHEB INHIBITORS AND USES THEREOF | RHEB, KRAS, NRAS | CYP11B1 223/4885CYP11B2 277/4885RAB9A 35/4885 |
| US-12071413-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | CYP11B1 263/4885CYP11B2 461/4885RAB9A 3035/4885 |
| US-11155525-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | CYP11B1 263/4885CYP11B2 461/4885RAB9A 3035/4885 |
| US-11339144-B2 | Heteroaryl Rheb inhibitors and uses thereof | RHEB, GDI2, KRAS | CYP11B1 130/4885CYP11B2 202/4885RAB9A 31/4885 |
| US-20200347022-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | CYP11B1 314/4885CYP11B2 501/4885RAB9A 2687/4885 |
| US-20220144784-A1 | NOVEL AZOLE DERIVATIVES AS APELIN RECEPTOR AGONIST | APLNR, AGTR1, AGTR2 | CYP11B1 303/4885CYP11B2 505/4885RAB9A 2791/4885 |
| US-10626096-B2 | Azole derivatives as apelin receptor agonist | APLNR, AGTR1, AGTR2 | CYP11B1 272/4885CYP11B2 469/4885RAB9A 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.